

April 9, 2013



BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican

Dr. Wayne Marasco to Talk at "Second International Vatican Adult Stem Cell Conference"

JUPITER, Fla., April 9, 2013 /PRNewswire/ -- **BioRestorative Therapies, Inc. ("BRT" or the "Company")** (OTCBB: BRTX), a life sciences company focused on adult stem cell based cellular therapies for various personal medical applications, announced today that Wayne Marasco, M.D., Ph.D., Chairman of BRT's Scientific Advisory Board, will be speaking at the *Second International Vatican Adult Stem Cell Conference: Regenerative Medicine -- A Fundamental Shift in Science and Culture*. The event will be held in Vatican City from April 11th to April 13th.

Dr. Marasco is a Professor of Medicine in the Department of Cancer Immunology & AIDS at Dana-Farber Cancer Institute and Harvard Medical School and will be speaking on April 13th during the session entitled "Stem Cells, Cancer and Aging — A Search for Solutions." His talk is titled "What Questions Haven't Been Addressed with Respect to Stem Cells, Cancer and Aging?"

"We are very excited to have Dr. Marasco be a featured speaker at the *Second International Vatican Adult Stem Cell Conference*," remarked Mark Weinreb, CEO of BRT. "He is extremely knowledgeable in the field of cellular biology, is a world-respected researcher and scientist, and has served exceptionally as the Chairman of our Scientific Advisory Board."

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT") develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, and allowing patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives: Our brtxDISC™ Program (**Disc Implanted Stem Cells**) offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. Our ThermoStem™ Program focuses on treatments, using brown fat stem cells, for metabolic disorders (diabetes, heart disease, etc.) and obesity primarily focusing on potentially preventing the onset of Type 2 Diabetes. Initial research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body. The Company also offers plant stem cell-based facial creams and products under the Stem Pearls® brand at www.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

KCSA Strategic Communications

Philip Carlson / Josh Dver

+1 212.896.1233 / +1 212.896.1239

pcarlson@kcsa.com / jdver@kcsa.com

SOURCE BioRestorative Therapies, Inc.